The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index; 16 of the 99 sources its claims cite were checked for support.
Indian Imaginaries of Chinese Success in the Global Herbal Medicine Market: A Critical Assessment
Abstract
<section class="abstract">Abstract India’s share in the global herbal market is dwarfed by that of China. Public and policy discourse in India exhorts Ayurvedic stakeholders to emulate Chinese medicine’s “science-based approach” to expand their global market share. But contrary to popular perception in India, China has been largely unsuccessful in making inroads into the coveted Euro-American herbal medicine market. Chinese medicine’s global footprint is largely the result of historical-cultural links, diasporic influences, and acupuncture practitioners. With national traditional medicine policies increasingly shaped by the evidence-based regulatory paradigm, the future of these informal bottom-up pathways is uncertain. Ignoring the roots of Chinese medicine’s global career has led to a distorted image of its “success” as an outcome of state investment in scientific validation and standardization programs. Our findings underscore the need to critically examine the imaginaries of success that drive stakeholders of non-biomedical traditions toward scientization to earn legitimacy and profits in the global realm. </section>
Overview
CoChat Summary
TL;DR
The paper argues that Indian policy and public discourse wrongly attributes Chinese medicine’s global herbal-market success to a science-based, state-led model, while China has in fact largely failed to penetrate Euro-American evidence-based herbal markets. It attributes Chinese medicine’s global footprint mainly to historical-cultural links, diasporic networks, acupuncture, and diplomatic pathways, and warns that this distorted imaginary pushes Ayurveda toward scientization.
Key findings
- India’s 2015–16 medicinal herb and herbal product exports were $358.6 million, about 0.5% of the global herbal market, while China’s exports were $3.8 billion, ten times India’s; however, in 2015 only 14.6% of Chinese herbal exports were finished products, with crude herbs and extracts over 80%.
- Chinese medicine has barely breached Euro-American regulatory pathways: as of 2015, only 2 of 1,577 EU Traditional Use Registrations and 1 of 768 Well-Established Use authorizations were based on Chinese herbal medicines; only one Chinese herbal medicine-based product had received USFDA botanical pathway approval since 2004.
- Most Chinese medicine sales are in Asian markets: East and Southeast Asia accounted for 60.7% of China’s raw and processed herbal medicine exports in 2015, and globalization also flowed through acupuncture, diaspora networks, and Cold War-era diplomatic/aid channels.
- The EU’s Traditional Herbal Medicinal Products Directive disrupted bottom-up pathways: Chinese medicine product exports increased 6.4% in 2011 but plunged 22% in 2012, and one forecast predicted around 100,000 Chinese medicine workers would lose jobs post-THMPD.
Methods
- Critical literature review over two years of over 1,000 English-language sources from PubMed, Science Direct, and Google Scholar, plus journals, press reports, industry reports, business case studies, and policy documents.
- Supplemented by Kudlu’s field notes from seven national and international Ayurvedic conferences in India between 2008 and 2016 and by Nichter’s professional network; the authors lacked access to Chinese-language journals and relied on key review articles citing Chinese-language sources.
- Analysis compares Indian claims of Chinese success with evidence on export composition, regulatory approvals, and bottom-up globalization pathways.
Limitations
- Stated: the primary aim is to flag discrepancies and provide pointers for further investigation; the scope is limited to Chinese medicine pharmaceuticals; and the authors did not have access to Chinese-language journals, relying instead on English sources and reviews citing Chinese-language sources.
- Evident: as a review, it does not present primary quantitative data or a systematic meta-analysis; the analysis of “Indian imaginaries” draws on selected scholarly, media, and policy sources plus conference field notes, so the representativeness of that discourse is not quantified.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 14 Not valid · 64 Not checked · 70 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“An illustrative case is that of the botanical Phy906, which has passed the USFDA's phase II trials as an adjuvant in several cancer therapies.”
What the sources say
- Partly supportedcites Kuo 2015 sourceExperimental — accuracy not yet measured
The ‘Regulatory Passage: The Reformulation of PHY906 via Trials’ section (page not available) describes PHY906 as an adjuvant tested with chemotherapy in several cancers, including phase II studies. It does not say PHY906 ‘passed’ FDA phase II trials; it says the researchers were modest about the pancreatic trial’s findings, its pharmacological role needed clarification, and the regulatory goal was still far ahead. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Trials are often terminated midway, because unfavorable results could jeopardize their current market.”
What the sources say
- Could not verifycites S. Chen et al. 2008, 1080 sourceExperimental — accuracy not yet measured
The discussion of dietary supplements and clinical testing (p. 1077) says that reporting clinical testing to the FDA is not required for certain marketed products. It does not say that trials are often terminated midway to protect an existing market. Searches for premature trial termination, unfavorable results, and commercial concerns found no passage addressing that claim. (LLM, conf=0.73)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“IND submissions are often misused by opportunistic manufacturers to claim scientific credentials for already-marketed dietary supplements, exploiting laypersons' inability to distinguish between INDs and approved drugs.”
What the sources say
- Could not verifycites S. Chen et al. 2008, 1080 sourceExperimental — accuracy not yet measured
In “From dietary supplements to new drugs” (p. 1077), the paper distinguishes dietary supplements from drugs; its discussion of IND submissions addresses regulatory review and prior human experience. The passages on supplement claims say those claims can be confusing, but do not say manufacturers misuse IND submissions to confer scientific credibility or that consumers confuse INDs with approved drugs. Searches for IND misuse, marketing of supplements, and promotion of IND status found no passage addressing that allegation. (LLM, conf=0.77)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“Wen-Hua Kuo's ethnography shows how the excitement over the drug gradually declined as it was dragged through a fifteen-year-long regulatory journey from innovation to publication of its phase II results in 2014.”
What the sources say
- Supportedcites Kuo 2015 source
In “Regulatory Passage: The Reformulation of PHY906 via Trials,” Kuo dates PHY906’s development from 1999 to publication of its first phase II study in 2014, calling it a 15-year regulatory passage. “Network in Expansion and Moving Targets” says PHY906 could not produce information quickly enough to sustain participants’ excitement and gradually disappeared from the consortium’s centre stage. (LLM, conf=0.92)
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, around 25 percent of the total applications are based on Chinese medicine herbs.”
What the sources say
- Partly supportedcites Tai-Ping Fan et al. 2012, 579 sourceExperimental — accuracy not yet measured
Section 2.11.2 says about a quarter of the INDs concern botanical products originating from TCM herbs. It separately counts more than 400 pre-INDs and INDs submitted to the FDA, but does not say that a quarter of all those applications concern TCM herbs. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
83 more claims · 2 with their cited sources checked
Create a free account to see all 162 claims and to verify the 3 references still open.
- Probably not a substantial claim. 50
- It may state two separate claims as one. 39
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Bottom-Up Pathways Restricted by Centralized Regulatory Regimes: the Case of the EU's Traditional Herbal Medicinal Products Directive · p. 14
“the THMPD of 2004, which took effect on April 30, 2011”
§ Bottom-Up Pathways Restricted by Centralized Regulatory Regimes: the Case of the EU's Traditional Herbal Medicinal Products Directive · p. 19
“after the THMPD's implementation in late 2011”
Citations
Cites
Ayurveda and Traditional Chinese Medicine: A Comparative Overview
Patwardhan, B., Warude, D., Pushpangadan, P., & Bhatt, N. (2005) · Evidence-Based Complementary and Alternative Medicine · doi:10.1093/ecam/neh140 · Cited by 856
THE WORLD MEDICINES SITUATION 2011 TRADITIONAL MEDICINES: GLOBAL SITUATION, ISSUES AND CHALLENGES
Robinson, M. M., & Zhang, X. (2011) · Cited by 498
WHO Global Atlas of Traditional, Complementary and Alternative Medicine
Bodeker, G., Ong, C. P., Grundy, C., Burford, G., & Shein, K. (2005) · LSHTM Research Online (London School of Hygiene and Tropical Medicine) · Cited by 449
Knowing Practice: The Clinical Encounter of Chinese Medicine.
Schipper, H., Minden, K., & Farquhar, J. (1995) · Pacific Affairs · doi:10.2307/2761379 · Cited by 367
Traditional Chinese medicine in the Chinese health care system
Xu, J., & Yang, Y. (2009) · Health Policy · doi:10.1016/j.healthpol.2008.09.003 · Cited by 321
The quest for modernisation of traditional Chinese medicine
Xu, Q., Bauer, R., Hendry, B. M., Fan, T.-P., Zhao, Z., Duez, P., Simmonds, M. S., Witt, C. M., Lu, A., Robinson, N., et al. (2013) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-13-132 · Cited by 215
Chinese Medicine in Contemporary China: Plurality and Synthesis
Scheid, V. (2002) · Duke University Press eBooks · doi:10.1215/9780822383710 · Cited by 201
Other-worldly: making Chinese medicine through transnational frames
(2010) · Choice Reviews Online · doi:10.5860/choice.48-0367 · Cited by 191
Herbal Drug Regulation and Commercialization: An Indian Industry Perspective
Bhattacharya, N. S., & Manchikanti, P. (2013) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2012.0275 · Cited by 178
Randomized Controlled Crime: Postcolonial Sciences in Alternative Medicine Research
Adams, V. (2002) · Social Studies of Science · doi:10.1177/030631270203200503 · Cited by 176
Research works printed but not linked: 15
- Agarwal, Paru, Shashi Alok, Amreen Fatima, and Amita Verma. 2013. 'Current Scenario of Herbal Technology Worldwide: An Overview.' International Journal of Pharmaceutical Sciences and Research 4(11): 4105-4117.
- Banerjee, Madhulika. 2004. 'Local Knowledge for World Market: Globalizing Ayurveda.' Economic and Political Weekly 39 (1): 89-93.
- Bode, Maarten. 2009. 'On the Effectiveness of Ayurvedic Medical Treatment: Humoral Pharmacology, Positivistic Science, and Soteriology.' Electronic Journal of Indian Medicine 2:1-24. Accessed November 10, 2017. https://ugp.rug.nl/eJIM/article/view/ 24718.
- Chi, Wenshu. 2015. 'Writing its Own Prescription.' Beijing Review . Accessed March 30, 2019. http://www.bjreview.com/Business/201511/t20151102\_800041718.html.
- China Economic Review. 2012. 'Africa Becomes Largest Export Market for Chinese Medicine.' November 5. Accessed March 30, 2019. http://www.chinaeconomic review.com/africa-becomes-largest-export-market-chinese-medicine.
- China Economic Review. 2013. 'Chinese Medicine Plays by Western Rules to Gain Acceptance.' July 5. Accessed March 30, 2019. http://www.chinaeconomicreview .com/traditional-Chinese-medicine-TCM-healthcare-pharmaceuticals-botanical -drugs-FDA.
- Clarke, Tainya C., Lindsey I. Black, Barbara J. Stussman, Patricia M. Barnes, and Richard L. Nahin. 2015. 'Trends in the Use of Complementary Health Approaches among Adults: United States, 2002-2012.' National Health Statistics Report 79:1-16. Accessed December 8, 2018. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573565/.
- Humes, Cynthia Ann. 2008. 'Maharishi Ayur-Veda: Perfect Health through Enlightened Marketing in America.' In Modern and Global Ayurveda: Pluralism and Paradigms , edited by D. Wujastyk and F. M. Smith, 309-32. Albany: State University of New York Press.
- Jasanoff, Sheila. 2015. 'Future Imperfect: Science, Technology, and the Imaginations of Modernity.' In Dreamscapes of Modernity: Sociotechnical Imaginaries and the Fabrication of Power , edited by S. Jasanoff and S. Kim, 1-33. Chicago: University of Chicago Press.
- Nichter, Mark, and Margaret Lock, eds. 2002. New Horizons in Medical Anthropology: Essays in Honor of Charles Leslie . London: Routledge.
- Pordié, Laurent, and Jean P. Gaudillière. 2014. 'The Reformulation Regime in Drug Discovery.' East Asian Science, Technology and Society 8 (1): 57-79.
- Press Information Bureau, Government of India, Ministry of Health and Family Welfare. 2014. 'Government to Push for Standardization in Ayurvedic Drug Production.' Accessed November 4, 2017. http://www.pib.nic.in/newsite/PrintRelease.aspx? relid=111136.
- Singh, R. H. 2015. 'Doing Ayush in India Today: Against all Odds.' Annals of Ayurvedic Medicine 4 (3-4): 62-63.
- Sujatha, V. 2011. 'What Could Integrative Medicine Mean?' Journal of Ayurveda and Integrative Medicine 2 (3): 115.
- Xiang, Lei, Jing Chen, Chun-Xiang Liu, Jia Lin, Jing Lou, and Hong-cai Shang. 2014. 'Status and Thoughts of Chinese Patent Medicines Seeking Approval in the US Market.' Chinese Journal of Integrative Medicine 20 (6): 403-8.
Cited by
Microbial Contaminants of Herbal Remedies: Health Risks and Sustainable Quality Control Strategies
Ovuru, K. F., Izah, S. C., Yasmin, H., Enerijiofi, K. E., Das, M., & Ogwu, M. C. (2023) · Reference series in phytochemistry · doi:10.1007/978-3-031-21973-3_9-1 · Cited by 17
Shah, P., Banerjee, S., Singh, A., Kulhari, H., & Saharan, V. A. (2025) · Wiley eBooks · doi:10.1002/9781119769484.ch1 · Cited by 17
Urquiza-Haas, N., & Cloatre, E. (2023) · Griffith Law Review · doi:10.1080/10383441.2023.2249708 · Cited by 6
Microbial Contaminants of Herbal Remedies: Health Risks and Sustainable Quality Control Strategies
Ovuru, K. F., Izah, S. C., Yasmin, H., Enerijiofi, K. E., Das, M., & Ogwu, M. C. (2024) · Reference series in phytochemistry · doi:10.1007/978-3-031-43199-9_9 · Cited by 8
Kudlu, C. (2025) · Frontiers in Human Dynamics · doi:10.3389/fhumd.2025.1549341 · Cited by 6
Self-citation
Metadata
- Authors
- Kudlu, C., & Nichter, M.
- Affiliations
- Independent Scholar
- University of Arizona (US)
- ORCID
- Nichter, Mark
- Venue
- Asian Medicine
- Publisher
- Walter de Gruyter GmbH
- Published
- 2019-09-02
- Volume
- 14
- Issue
- 1
- Pages
- 104-144
- ISSN
- 1573-420X (ISSN-L)
- 1573-4218
- OpenAlex
- W2972843075
- Cited by
- 7
- References
- 62
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 2 · 2022: 1
- FWCI
- 0.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Asian Medicine (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Herbal Medicine and Trade Cooperation
- Health Sciences › Medicine › Complementary and alternative medicine › Traditional Chinese Medicine Studies
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Keywords
- traditional Chinese medicine, herbal medicine market, Ayurveda, scientization, traditional medicine policy, evidence-based regulation, acupuncture, international expansion, India-China comparison
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Indian Imaginaries of Chinese Success in the Global Herbal Medicine Market: A Critical Assessment. https://app.cochat.ai/papers/10.1163/15734218-12341437
- The paper
- Kudlu, C., & Nichter, M. (2019). Indian Imaginaries of Chinese Success in the Global Herbal Medicine Market: A Critical Assessment. Asian Medicine. https://doi.org/10.1163/15734218-12341437
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.